Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia

Waldenström macroglobulinemia (WM) is a distinct type of indolent lymphoplasmacytic lymphoma (LPL) with a high frequency of MYD88(L265P) mutation. Treatment for WM/LPL is highly variable in clinic and ibrutinib (a Bruton tyrosine kinase inhibitor, BTKi) has become a new treatment option for WM. To i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yingjun, Gali, Vasantha Lakshmi, Xu-Monette, Zijun Y., Sano, Dahlia, Thomas, Sheeba K., Weber, Donna M., Zhu, Feng, Fang, Xiaosheng, Deng, Manman, Zhang, Mingzhi, Hagemeister, Fredrick B., Li, Yong, Orlowski, Robert Z., Lee, Hans Chulhee, Young, Ken H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985670/
https://www.ncbi.nlm.nih.gov/pubmed/33735664
http://dx.doi.org/10.1016/j.neo.2021.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985670/
https://www.ncbi.nlm.nih.gov/pubmed/33735664
http://dx.doi.org/10.1016/j.neo.2021.02.002

Ejemplares similares